PATENT CLAIM ANALYSIS

Application Number: 15747507
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "640000"]

Abstract:
The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Claim (Index 19):
Cationic compound according to  claim 18 , wherein the disease or the condition is chosen among pulmonary hypertension, such as pulmonary arterial hypertension or thromboembolic pulmonary hypertension, pulmonary diseases involving inflammation, fibrosis and remodeling such as asthma, non-neuronal cancers such as colon, breast, lung or thyroid carcinoma, diabetes, atherosclerosis, sickle cell disease, diseases involving thrombosis, acute infections such as ARDS syndrome or ALI, chronic infectious diseases such as gastric ulcer induced by  Helicobacter pylori , inflammatory/autoimmune diseases such as rheumatoid arthritis and irritable Bowel syndrome and osteoarthritis, heart failure, arrhythmias, renal disorders, pain, in particular peripheral neuropathic pain, psoriasis, atopic dermatitis and osteoporosis.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14399945', '13129916', '15560265', '14738148', '15552997']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7487912438065124
- 35 USC 102 Novelty (BERT): 0.5184763379152625
- Combined Prediction Score: 0.7257597532173874
- Mean Citation Score: 264.37507200000005
- Max Citation Score: 271.68488
- Similarity Product: 184.45525429139136

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test